secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001683168-24-001049
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Majority shareholder approves warrant adjustments for Sunshine Biopharma
------------------------------------------------------------------------

- Dr. Steve Slilaty (CEO, 58.3% voting power) approved written consent on Feb 13, 2024.
- Consent covers alternative cashless exercise for Series A Warrants and adjustments upon share combination.
- Also includes voluntary exercise price adjustments, Floor Price clause inapplicability for Series B, and dilutive issuance adjustments.
- Effective 20 days after mailing information statement to shareholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-001049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer